Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
Preclinical and early clinical development is expensive enough already for VC companies but it gets really expensive in Phase 3. Hence, not surprisingly, few small companies tackle Phase 3 programs on their own. Unless an ‘angel investor’ with deep pockets commits to the compound and assures continuity of development, the Continue reading The Difficult Transition Into Phase 3
Looking at all antibiotics in the pipeline, I can’t help but think that – by 2018 – there will be some blockbuster anti-infectives coming to the market. Why do I say this? What is going to generate this revenue stream for companies when the new crop of drugs will be restricted by Continue reading Why The Next Novel Antibiotic Will Be A Blockbuster And Cost $40k
After a single high dose of (8 or 10 mg/kg BW) of daptomycin IV, bone levels were measured in plasma and trabecular bone obtained during hip or knee surgery of 16 patients.[1] At the time of surgery, mean concentrations in plasma and synovial fluid were 39 and 22 µg/mL, respectively. Continue reading Adequate Penetration of Daptomycin Into Bone Tissue